Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

• Clearmind Medicine completed dosing for Part A of its FDA-regulated Phase I/II trial of CMND-100 in Alcohol Use Disorder.
• Interim results from the first three cohorts were already presented, indicating a favorable safety profile without detailing efficacy metrics.
• The study is a multicenter, randomized, double-blind, placebo-controlled trial run under an FDA IND.
• Part A treated 24 healthy participants across four escalating-dose cohorts, supporting progression to later-stage trial activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160732PRIMZONEFULLFEED9747681) on June 16, 2026, and is solely responsible for the information contained therein.